Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Status Active, not recruiting

Clinical Trial Summary

The purpose of this research is to test if a combination treatment of nivolumab and relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.

Clinical Trial Description

This is a phase II single-institution trial with a Simon two-stage minimax design with 27 patients (13 in stage 1, 14 in stage 2) setting a 5% type I error and 80% power under true objective response rate (ORR) of 20%. The null hypothesis (ORR=5%) is rejected if 4 or more responses are observed in 27 patients. No prior PD-1, CTLA-4 and/or LAG-3 blocking antibody treatment was allowed. We will also perform single-cell mRNA and T-cell receptor (TCR) variable, diversity, and joining (V[D]J) sequencing pre-treatment and at either progression or response. Patients will be treated with nivolumab 480 mg/relatlimab 160 mg IV q4wks to progression or intolerable toxicity for up to two years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04552223
Study type	Interventional
Source	University of Miami
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 10, 2020
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03068624` - Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma	Phase 1
Recruiting	`NCT04728633` - Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases	Phase 2
Recruiting	`NCT05987332` - IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma	Phase 2/Phase 3
Completed	`NCT01551459` - A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma	Phase 2
Active, not recruiting	`NCT00986661` - A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Phase 1
Completed	`NCT01585194` - Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma	Phase 2
Withdrawn	`NCT01328106` - Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma	Phase 2
Recruiting	`NCT05075993` - Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05607095` - Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma	Phase 1
Active, not recruiting	`NCT01587352` - Vorinostat in Treating Patients With Metastatic Melanoma of the Eye	Phase 2
Active, not recruiting	`NCT03472586` - Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver	Phase 2
Active, not recruiting	`NCT03025256` - Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease	Phase 1
Terminated	`NCT04879017` - FHD-286 in Subjects With Metastatic Uveal Melanoma	Phase 1
Terminated	`NCT01814046` - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma	Phase 2
Recruiting	`NCT03947385` - Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Phase 1/Phase 2
Active, not recruiting	`NCT03865212` - Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma	Phase 1
Active, not recruiting	`NCT05022901` - An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma	Phase 3
Recruiting	`NCT05282901` - Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)	Phase 2
Recruiting	`NCT05415072` - A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas	Phase 1/Phase 2
Active, not recruiting	`NCT04720417` - Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma	Phase 2